Rui Wang

Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms

The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD), and subsequently to metabolic dysfunction-associated steatotic liver disease (MASLD), signals a paradigm shift that repositions hepatic steatosis as a systemic metabolic disorder rather than a diag...